Latest research on Capecitabine

Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.

Capecitabine interactions

In both the FAS and PAS (respectively), Paclitaxel (26% and 25%), Docetaxel (17% and 18%), trastuzumab (14% and 11%), Vinorelbine (12% and 11%), and Capecitabine (9% and 11%) were the most commonly used agents in “non-standard” regimens. [source, 2016]
In patients with colorectal cancer in the FAS and PAS (n=153 and n=71, respectively), 5-Fluorouracil (5-FU) plus Oxaliplatin (14% in both populations), 5-FU plus Irinotecan (13% and 20%), Capecitabine plus Oxaliplatin (12% and 10%), and 5-FU plus Irinotecan plus bevacizumab (9% and 11%) were the most common “standard” regimens. [source, 2016]
A regimen combining the oral agent Capecitabine with Oxaliplatin (XELOX) was developed for the treatment of colorectal cancer. [source, 2016]
Based on growth inhibition of 60 human cancer cell lines (NCI60) subjected to Cisplatin, Epirubicine and Capecitabine, in addition to, baseline miRNA expression of the 60 cell lines, a miRNA-based response predictor to the three chemotherapeutic agents was developed. [source, 2016]
All patients had been treated with perioperative chemotherapy with Cisplatin, Epirubicine and Capecitabine. [source, 2016]
To evaluate the correlation between miRNA expression and drug sensitivity, growth inhibition (GI50) vectors of 60 cell lines subjected to Cisplatin, Epirubicine and Capecitabine were downloaded from the DTP web site. [source, 2016]
Hence, a miRNA response profile was developed in which expression levels were correlated to the sensitivity of Cisplatin, Epirubicine and Capecitabine. [source, 2016]
Using the NCI60 cell line panel, sensitivity towards Cisplatin, Epirubicine and Capecitabine was correlated to the baseline miRNA expression of 1756 human miRNAs and other small nucleolar RNAs in the same cell lines. [source, 2016]
In this study, a miRNA profile predictive for sensitivity to Cisplatin, Epirubicine and Capecitabine was developed in 53 patients with gastrooesophageal cancer. [source, 2016]
Capecitabine is a prodrug that is enzymatically converted to 5-Fluorouracil in the body. [source, 2016]